Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes

NCT05362058 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05362058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 3, 2022
Completion date
April 10, 2024
Enrollment
928 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 2 diabetes